晶科能源(688223.SH)IPO認購結果:網上網下共棄購122.08萬股
格隆匯1月20日丨晶科能源(688223.SH)公佈首次公開發行股票並在科創板上市發行結果公吿,本次發行最終戰略配售結果如下:


網上網下新股認購情況:
網上、網下投資者放棄認購股數全部由中信建投證券包銷,中信建投證券包銷股份的數量為122.0795萬股,包銷金額為610.3975萬元,包銷股份數量佔扣除戰略配售數量後發行數量的比例為0.0872%,包銷股份數量佔本次發行總規模的比例為0.0610%。
其中,網上投資者放棄認購數量為1,220,795股,網上投資者放棄認購金額為6,103,975.00元;網下投資者放棄認購數量為0股,網下投資者放棄認購金額為0.00元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.